Alyeska Investment Group
ABOS icon

Alyeska Investment Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Alyeska Investment Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.78M Buy
2,454,754
+1,515,151
+161% +$3.86M 0.02% 457
2025
Q4 		$1.98M Hold
939,603
– – 0.01% 523
2025
Q3 		$1.61M Hold
939,603
– – ﹤0.01% 519
2025
Q2 		$1.09M Hold
939,603
– – ﹤0.01% 502
2025
Q1 		$1.03M Hold
939,603
– – ﹤0.01% 436
2024
Q4 		$1.62M Hold
939,603
– – 0.01% 472
2024
Q3 		$2.33M Hold
939,603
– – 0.01% 408
2024
Q2 		$2.27M Hold
939,603
– – 0.01% 402
2024
Q1 		$3.81M Buy
939,603
+206,400
+28% +$778K 0.02% 345
2023
Q4 		$2.82M Buy
733,203
+119,381
+19% +$354K 0.02% 346
2023
Q3 		$2.55M Buy
+613,822
New +$3.79M 0.02% 373

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group's ABOS Position: Q1 2026 in Review

Alyeska Investment Group increased its Acumen Pharmaceuticals (ABOS) stake by 161% in Q1 2026, buying an estimated $3.86M and bringing the position to 2,454,754 shares worth $5.78M. The position accounts for 0.02% of the portfolio, ranked #457.

Alyeska Investment Group first reported a position in ABOS in Q3 2023 and has held it in 11 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Alyeska Investment Group held 2,454,754 shares of Acumen Pharmaceuticals worth $5.78M as of Q1 2026.
  • Alyeska Investment Group bought 1,515,151 Acumen Pharmaceuticals shares in Q1 2026, an estimated $3.86M.
  • Acumen Pharmaceuticals made up 0.02% of Alyeska Investment Group's portfolio in Q1 2026, its #457 holding.
  • Alyeska Investment Group first reported a position in Acumen Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.